<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="137819">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01826981</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-337-0122</org_study_id>
    <nct_id>NCT01826981</nct_id>
  </id_info>
  <brief_title>Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Subjects With Chronic Genotype 1, 2, 3, or 6 HCV Infection</brief_title>
  <official_title>A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <authority>New Zealand: Medsafe</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and antiviral efficacy of
      combination therapy with regimens containing sofosbuvir (SOF) for the treatment of genotype
      (GT) 1, 2, 3, or 6 chronic hepatitis C virus (HCV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</measure>
    <time_frame>Posttreatment Week 12</time_frame>
    <safety_issue>No</safety_issue>
    <description>SVR12 is defined as HCV RNA &lt; lower limit of quantification (LLOQ) 12 weeks after last dose of study drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with adverse events leading to permanent discontinuation of study drug(s)</measure>
    <time_frame>Baseline up to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with SVR through posttreatment Week 24</measure>
    <time_frame>Baseline to Posttreatment Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sustained virologic response (SVR) is defined as HCV RNA &lt; LLOQ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with on-treatment virologic failure and relapse</measure>
    <time_frame>Baseline to Posttreatment Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Viral breakthrough is defined as having achieved undetectable HCV RNA levels (HCV RNA &lt; LLOQ) during treatment, but did not achieve a sustained virologic response (SVR).
Viral relapse is defined as having achieved undetectable HCV RNA levels (HCV RNA &lt; LLOQ) within 4 weeks of end of treatment, but did not achieve an SVR.</description>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Anticipated">410</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV (GT1) Retreatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Retreatment participants with genotype 1 HCV infection will receive LDV/SOF FDC+RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+PEG+RBV (GT2/3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Retreatment participants with genotype 2 or 3 HCV infection will receive SOF+PEG+RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV (GT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis will receive LDV/SOF FDC+RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF+GS-9669 (GT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-experienced participants with genotype 1 HCV infection and advanced liver fibrosis or compensated liver fibrosis will receive LDV/SOF FDC+GS-9669 for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF (GT3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive participants with genotype 3 HCV infection will receive LDV/SOF FDC for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV (GT3) TN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive (TN) participants with genotype 3 HCV infection will receive LDV/SOF FDC+RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF (GT6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive or treatment-experienced participants with genotype 6 HCV infection will receive LDV/SOF FDC for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF+RBV (GT3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-experienced participants with genotype 3 HCV infection will receive LDV/SOF FDC+RBV for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF (GT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1 HCV infection, who are Child-Pugh Class B, will receive LDV/SOF FDC for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+GS-5816 25 mg (GT3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive participants with genotype 3 HCV infection will receive SOF+GS-5816 25 mg for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+GS-5816 25 mg+RBV (GT3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive participants with genotype 3 HCV infection will receive SOF+GS-5816 25 mg + RBV for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+GS-5816 100 mg (GT3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive participants with genotype 3 HCV infection will receive SOF+GS-5816 100 mg for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF+GS-5816 100 mg+RBV (GT3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive participants with genotype 3 HCV infection will receive SOF+GS-5816 100 mg+RBV for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF FDC + RBV (GT1, 2, 3, 6) Retreatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Retreatment participants with genotypes 1, 2, 3, or 6 HCV infection will receive LDV/SOF FDC+RBV for 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LDV/SOF FDC (GT1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with genotype 1 HCV and hepatitis B virus (HBV) coinfection will receive LDV/SOF FDC for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LDV/SOF FDC</intervention_name>
    <description>Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet administered orally once daily</description>
    <arm_group_label>LDV/SOF+RBV (GT1) Retreatment</arm_group_label>
    <arm_group_label>LDV/SOF+RBV (GT1)</arm_group_label>
    <arm_group_label>LDV/SOF+GS-9669 (GT1)</arm_group_label>
    <arm_group_label>LDV/SOF (GT3)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV (GT3) TN</arm_group_label>
    <arm_group_label>LDV/SOF (GT6)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV (GT3)</arm_group_label>
    <arm_group_label>LDV/SOF (GT1)</arm_group_label>
    <arm_group_label>LDV/SOF FDC + RBV (GT1, 2, 3, 6) Retreatment</arm_group_label>
    <arm_group_label>LDV/SOF FDC (GT1)</arm_group_label>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
    <other_name>GS-5885</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOF</intervention_name>
    <description>SOF 400 mg tablet administered orally once daily</description>
    <arm_group_label>SOF+PEG+RBV (GT2/3)</arm_group_label>
    <arm_group_label>SOF+GS-5816 25 mg (GT3)</arm_group_label>
    <arm_group_label>SOF+GS-5816 25 mg+RBV (GT3)</arm_group_label>
    <arm_group_label>SOF+GS-5816 100 mg (GT3)</arm_group_label>
    <arm_group_label>SOF+GS-5816 100 mg+RBV (GT3)</arm_group_label>
    <other_name>GS-7977</other_name>
    <other_name>PSI-7977</other_name>
    <other_name>SovaldiÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RBV</intervention_name>
    <description>Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (&lt; 75 kg = 1000 mg and â¥ 75 kg = 1200 mg)</description>
    <arm_group_label>LDV/SOF+RBV (GT1) Retreatment</arm_group_label>
    <arm_group_label>SOF+PEG+RBV (GT2/3)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV (GT1)</arm_group_label>
    <arm_group_label>LDV/SOF+RBV (GT3) TN</arm_group_label>
    <arm_group_label>LDV/SOF+RBV (GT3)</arm_group_label>
    <arm_group_label>SOF+GS-5816 25 mg+RBV (GT3)</arm_group_label>
    <arm_group_label>SOF+GS-5816 100 mg+RBV (GT3)</arm_group_label>
    <arm_group_label>LDV/SOF FDC + RBV (GT1, 2, 3, 6) Retreatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG</intervention_name>
    <description>Peginterferon alfa-2b (PEG) 180 Âµg administered subcutaneously once weekly</description>
    <arm_group_label>SOF+PEG+RBV (GT2/3)</arm_group_label>
    <other_name>PegasysÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-9669</intervention_name>
    <description>GS-9669 250 mg tablet administered orally once daily</description>
    <arm_group_label>LDV/SOF+GS-9669 (GT1)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GS-5816</intervention_name>
    <description>GS-5816 25 mg or 100 mg tablet(s) administered orally once daily</description>
    <arm_group_label>SOF+GS-5816 25 mg (GT3)</arm_group_label>
    <arm_group_label>SOF+GS-5816 25 mg+RBV (GT3)</arm_group_label>
    <arm_group_label>SOF+GS-5816 100 mg (GT3)</arm_group_label>
    <arm_group_label>SOF+GS-5816 100 mg+RBV (GT3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal to or greater than 18 years, with chronic genotype 1, 2, 3, or 6 HCV
             infection

          -  HCV RNA equal to or greater than 10,000 IU/mL at Screening

          -  Cirrhosis determination; a liver biopsy may be required

          -  Screening laboratory values within defined thresholds

          -  Use of two effective contraception methods if female of childbearing potential or
             sexually active male

        Exclusion Criteria:

          -  Pregnant or nursing female or male with pregnant female partner

          -  Hepatocellular carcinoma (HCC) or other malignancy (with exception of certain
             -resolved skin cancers)

          -  Chronic use of systemic immunosuppressive agents

          -  History of clinically significant illness or any other medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rob Hyland, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raja Vakil</last_name>
    <email>raja.vakil@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Auckland Clinical Studies Ltd.</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Christchurch Clinical Studies Trust</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>April 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV genotype 1 (GT-1)</keyword>
  <keyword>HCV genotype 2 (GT-2)</keyword>
  <keyword>HCV genotype 3 (GT-3)</keyword>
  <keyword>HCV genotype 2 or 3 (GT-2/3)</keyword>
  <keyword>HCV genotype 6 (GT-6)</keyword>
  <keyword>HCV</keyword>
  <keyword>Sustained Virologic Response</keyword>
  <keyword>Direct Acting Antiviral</keyword>
  <keyword>Combination Therapy</keyword>
  <keyword>Ribavirin</keyword>
  <keyword>PEG</keyword>
  <keyword>Open Label</keyword>
  <keyword>Sofosbuvir</keyword>
  <keyword>Ledipasvir</keyword>
  <keyword>GS-9669</keyword>
  <keyword>GS-7977</keyword>
  <keyword>GS-5885</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
